Massachusetts Medicaid and semaglutide
Wegovy for weight loss: no. Not covered when used only for obesity or overweight. Still approvable with prior authorization for heart disease with BMI above 27, sleep apnea with BMI above 30, or MASH, and for members under 21 when medically necessary under EPSDT. Ozempic for weight loss: no; for type 2 diabetes Massachusetts Medicaid must cover it. Read from Massachusetts Executive Office of Health and Human Services, MassHealth documents Nov 6, 2026.
In 2025 Massachusetts Medicaid paid for 53,347 semaglutide prescriptions (Ozempic, Wegovy, Rybelsus), 13% of its GLP-1 prescriptions and 22nd of the 50 states and DC. It reimbursed $50.8 million before rebates, $952 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 41,461 | $38.9 million | $937 |
| Wegovy | 9,167 | $9.4 million | $1,022 |
| Rybelsus | 2,719 | $2.5 million | $933 |
Massachusetts plans and prescribing rules
Massachusetts Group Insurance Commission (GIC). The GIC voted to end coverage of GLP-1s for obesity alone. From July 1, 2026, GIC plans cover them only for diabetes, or for members with a BMI of 27 or higher and an FDA-approved comorbid condition.
Semaglutide in the states around Massachusetts
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| Massachusetts | 18 | $39/moWellmedr | 53,347 | Medicaid Wegovy: No |
| Connecticut | 19 | $39/moWellmedr | 107,061 | Medicaid Wegovy: No |
| New Hampshire | 19 | $39/moWellmedr | 21,492 | Medicaid Wegovy: No |
| New York | 19 | $39/moWellmedr | 488,820 | Medicaid Wegovy: No |
| Rhode Island | 19 | $39/moWellmedr | 29,679 | Medicaid Wegovy: Not confirmed (KFF) |
| Vermont | 19 | $39/moWellmedr | 8,393 | Medicaid Wegovy: No |



